164 related articles for article (PubMed ID: 32014905)
1.
Yamashita H; Ishida N; Hatanaka Y; Hagio K; Oshino T; Takeshita T; Kanno-Okada H; Shimizu AI; Hatanaka KC; Matsuno Y
Anticancer Res; 2020 Feb; 40(2):645-652. PubMed ID: 32014905
[TBL] [Abstract][Full Text] [Related]
2. p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.
Yamamoto M; Hosoda M; Nakano K; Jia S; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Cancer Sci; 2014 Jan; 105(1):81-8. PubMed ID: 24118529
[TBL] [Abstract][Full Text] [Related]
3. Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer.
Ogiya A; Yamazaki K; Horii R; Shien T; Horimoto Y; Masuda N; Inao T; Hosoda M; Ishida N; Osako T; Takahashi M; Endo Y; Miyoshi Y; Yasojima H; Tomioka N; Yamashita H;
Breast Cancer; 2017 May; 24(3):473-482. PubMed ID: 27628678
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation.
Sekido Y; Umemura S; Takekoshi S; Suzuki Y; Tokuda Y; Tajima T; Osamura RY
Int J Oncol; 2003 Jun; 22(6):1225-32. PubMed ID: 12738987
[TBL] [Abstract][Full Text] [Related]
6. Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
Luen SJ; Asher R; Lee CK; Savas P; Kammler R; Dell'Orto P; Biasi OM; Demanse D; JeBailey L; Dolan S; Hackl W; Thuerlimann B; Viale G; Colleoni M; Regan MM; Loi S
JAMA Oncol; 2018 Oct; 4(10):1335-1343. PubMed ID: 29902286
[TBL] [Abstract][Full Text] [Related]
7. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.
Miyoshi Y; Shien T; Ogiya A; Ishida N; Yamazaki K; Horii R; Horimoto Y; Masuda N; Yasojima H; Inao T; Osako T; Takahashi M; Tomioka N; Endo Y; Hosoda M; Doihara H; Miyoshi S; Yamashita H;
Breast Cancer Res; 2016 Jul; 18(1):73. PubMed ID: 27368476
[TBL] [Abstract][Full Text] [Related]
8. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.
Park YH; Lee S; Cho EY; Choi YL; Lee JE; Nam SJ; Yang JH; Ahn JS; Im YH
Cancer Chemother Pharmacol; 2010 Aug; 66(3):507-16. PubMed ID: 19956951
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
10. Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status.
Payandeh M; Shahriari-Ahmadi A; Sadeghi M; Sadeghi E
Asian Pac J Cancer Prev; 2016; 17(3):1015-8. PubMed ID: 27039719
[TBL] [Abstract][Full Text] [Related]
11. Early onset HER2-positive breast cancer is associated with germline TP53 mutations.
Melhem-Bertrandt A; Bojadzieva J; Ready KJ; Obeid E; Liu DD; Gutierrez-Barrera AM; Litton JK; Olopade OI; Hortobagyi GN; Strong LC; Arun BK
Cancer; 2012 Feb; 118(4):908-13. PubMed ID: 21761402
[TBL] [Abstract][Full Text] [Related]
12. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
13. Opposite Prognostic Impact of Single PTEN-loss and
Lazaridis G; Kotoula V; Vrettou E; Kostopoulos I; Manousou K; Papadopoulou K; Giannoulatou E; Bobos M; Sotiropoulou M; Pentheroudakis G; Efstratiou I; Papoudou-Bai A; Psyrri A; Christodoulou C; Gogas H; Koutras A; Timotheadou E; Pectasides D; Zagouri F; Fountzilas G
Cancer Genomics Proteomics; 2019; 16(3):195-206. PubMed ID: 31018950
[TBL] [Abstract][Full Text] [Related]
14. Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania.
Pajenga E; Rexha T; Çeliku S; Ugrinska A; Bejtja G
Cent Eur J Public Health; 2016 Sep; 24(3):171-175. PubMed ID: 27760283
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
16. Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.
Ning SF; Li JL; Luo CP; Wei CH; Lu YK; Liu HZ; Wei WE; Zhang LT
Int J Clin Exp Pathol; 2014; 7(12):8740-7. PubMed ID: 25674240
[TBL] [Abstract][Full Text] [Related]
17. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
[TBL] [Abstract][Full Text] [Related]
18. Status of HER2 amplification, polysomy 17 and histopathological features of 425 Pakistani breast cancer patients.
Moatter T; Aban M; Iqbal W; Azam I; Pervaiz A; Siddiqui F; Murad F; Pervez S
Asian Pac J Cancer Prev; 2011; 12(11):3069-73. PubMed ID: 22393991
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer.
Tomiguchi M; Yamamoto Y; Yamamoto-Ibusuki M; Goto-Yamaguchi L; Fujiki Y; Fujiwara S; Sueta A; Hayashi M; Takeshita T; Inao T; Iwase H
Cancer Sci; 2016 Apr; 107(4):491-8. PubMed ID: 26801869
[TBL] [Abstract][Full Text] [Related]
20. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
